Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Historical outcomes are shown only after a prediction has matured and been evaluated.
Absolute percentage error: 2.39%
Absolute percentage error: 3.53%
Only stories explicitly associated with this stock are shown.
Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior, driven by improved medical cost trends and better execution. The company expects Medicaid membership to decline 8%-9% in 2026, but profitability improvements in Marketplace and Medicare segments, combined with higher Medicaid rates and cost initiatives, support continued recovery. CNC reaffirmed its 2026 adjusted EPS guidance above $4.80.
The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.
CVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of $6B. The company maintained its full-year 2026 outlook despite 340B program adjustments.
The global telepsychiatry market is projected to grow from USD 10.71 billion in 2025 to USD 70.95 billion by 2035 at a CAGR of 20.81%, driven by psychiatrist shortages, reimbursement reforms, and increased adoption of virtual mental healthcare. North America leads with 32% market share, while Asia Pacific shows the fastest growth. Key trends include AI-driven patient matching, employer-sponsored programs, and integration with primary care.
Tenet Healthcare (THC) is experiencing strong growth driven by higher-acuity services, robust commercial revenues, and expansion of its USPI ambulatory care platform. The company raised its 2026 EBITDA outlook and continues to balance growth investments with share buybacks. However, rising operating expenses from elevated labor costs and medical supplies pose a margin pressure risk.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
UNH is currently shown at $375.26 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
US Market AI currently shows quantitative forecasts for 24H, 7D, 30D and 90D using the stored market signals. The forecasts are estimates and not guarantees.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
Only predictions that have matured are evaluated. Recent evaluated outcomes are shown in the model-validation section; accuracy should be interpreted using the full mature sample rather than a single result.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
Explore other active stocks in the same sector.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.